Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox vs Xeomin in Blepharospasm
NCT00761592Phase 4Completed
- Sponsor
- Allergan
- Start
- Jul 2006
- Primary completion
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of onabotulinumtoxinA and botulinum neurotoxin in benign essential blepharospasm (BEB) (2 arms), sponsored by Allergan. Primary endpoint: Blepharospasm Disability Index at 4 weeks. Started Jul 2006; status: completed.
02
Drugs
onabotulinumtoxinAbotulinum neurotoxin
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT00761592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761592.